AR074603A1 - Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit - Google Patents

Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit

Info

Publication number
AR074603A1
AR074603A1 ARP090104820A ARP090104820A AR074603A1 AR 074603 A1 AR074603 A1 AR 074603A1 AR P090104820 A ARP090104820 A AR P090104820A AR P090104820 A ARP090104820 A AR P090104820A AR 074603 A1 AR074603 A1 AR 074603A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
octreotide
composition according
tumors
kit
Prior art date
Application number
ARP090104820A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40520410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR074603(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR074603A1 publication Critical patent/AR074603A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Reivindicación 1: Una composición farmacéutica de liberación sostenida, la cual comprende dos polímeros de poli-láctido-co-glicólido (PLGAs) lineales diferentes y, como ingrediente activo, octreotida, o una sal farmacéuticamente aceptable de la misma, en donde la concentración en plasma del ingrediente activo en conejos, con una dosificación de 12 miligramos/kilogramo, es constantemente más alta que 1,5 nanogramos/mililitro durante cuando menos 50 días. Reivindicación 10: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 9, la cual comprende la sal de pamoato de octreotida. Reivindicación 12: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 11, en la forma de micropartículas, un semi-sólido, o un implante. Reivindicación 17: El uso de una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 16, para la terapia de mantenimiento de largo plazo en los pacientes acromegálicos, y para el tratamiento de diarrea y evacuación repentina grave asociada con tumores carcinoides malignos y con tumores peptídicos intestinales vasoactivos (tumores de vipoma).
ARP090104820A 2008-12-15 2009-12-11 Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit AR074603A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08171712 2008-12-15

Publications (1)

Publication Number Publication Date
AR074603A1 true AR074603A1 (es) 2011-01-26

Family

ID=40520410

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104820A AR074603A1 (es) 2008-12-15 2009-12-11 Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit

Country Status (26)

Country Link
US (9) US20100151033A1 (es)
EP (1) EP2376070B1 (es)
JP (1) JP5721635B2 (es)
KR (1) KR101708517B1 (es)
CN (3) CN105031607A (es)
AR (1) AR074603A1 (es)
AU (1) AU2009336718B9 (es)
BR (1) BRPI0922607B1 (es)
CA (1) CA2746968C (es)
CL (1) CL2011001438A1 (es)
CO (1) CO6382109A2 (es)
EC (1) ECSP11011199A (es)
ES (1) ES2602614T3 (es)
HK (1) HK1159505A1 (es)
IL (1) IL213034A (es)
MA (1) MA32964B1 (es)
MX (1) MX2011006335A (es)
MY (1) MY159789A (es)
NZ (1) NZ592998A (es)
PE (1) PE20110876A1 (es)
PL (1) PL2376070T3 (es)
PT (1) PT2376070T (es)
RU (1) RU2526822C2 (es)
SG (1) SG171255A1 (es)
TN (1) TN2011000261A1 (es)
WO (1) WO2010079047A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011002836A (es) 2008-09-17 2011-04-28 Chiasma Inc Composiciones farmaceúticas y métodos de administración relacionados.
US10071061B2 (en) * 2012-05-14 2018-09-11 Teijin Limited Sterile composition
WO2015149820A1 (en) * 2014-03-31 2015-10-08 Pharmathen S.A. Preparation of peptide loaded plga microspheres with controlled release characteristics
AU2015360485B2 (en) 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
CN105963258B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
JP7344196B2 (ja) * 2017-09-15 2023-09-13 オクラー リミテッド 眼科用薬物組成物
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
GB9513224D0 (en) * 1995-06-29 1995-09-06 Sandoz Ltd Organic compounds
EP1581181B1 (en) * 2002-11-06 2008-12-24 ALZA Corporation Controlled release depot formulations
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
AU2005316545A1 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
CA2631811C (en) * 2005-12-22 2017-06-20 Novartis Ag Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers

Also Published As

Publication number Publication date
NZ592998A (en) 2013-02-22
CA2746968C (en) 2016-10-04
BRPI0922607A2 (pt) 2015-12-22
JP2012512147A (ja) 2012-05-31
AU2009336718A1 (en) 2011-06-30
CL2011001438A1 (es) 2011-11-04
WO2010079047A3 (en) 2010-09-16
RU2526822C2 (ru) 2014-08-27
US20240082148A1 (en) 2024-03-14
US20170143791A1 (en) 2017-05-25
CN102245210A (zh) 2011-11-16
ECSP11011199A (es) 2011-08-31
US20160089336A1 (en) 2016-03-31
CA2746968A1 (en) 2010-07-15
CN105233251A (zh) 2016-01-13
ES2602614T3 (es) 2017-02-21
AU2009336718B9 (en) 2014-04-03
TN2011000261A1 (en) 2012-12-17
US20110262545A1 (en) 2011-10-27
EP2376070A2 (en) 2011-10-19
IL213034A0 (en) 2011-07-31
US20100151033A1 (en) 2010-06-17
JP5721635B2 (ja) 2015-05-20
BRPI0922607B1 (pt) 2019-11-05
KR20110104042A (ko) 2011-09-21
HK1159505A1 (zh) 2012-08-03
US20210161806A1 (en) 2021-06-03
EP2376070B1 (en) 2016-08-10
PL2376070T3 (pl) 2017-04-28
US20140363513A1 (en) 2014-12-11
WO2010079047A2 (en) 2010-07-15
PT2376070T (pt) 2016-11-16
AU2009336718B2 (en) 2014-01-30
MX2011006335A (es) 2011-07-13
US20180036230A1 (en) 2018-02-08
US20190209462A1 (en) 2019-07-11
SG171255A1 (en) 2011-07-28
CO6382109A2 (es) 2012-02-15
CN105031607A (zh) 2015-11-11
MA32964B1 (fr) 2012-01-02
PE20110876A1 (es) 2011-12-21
KR101708517B1 (ko) 2017-02-20
IL213034A (en) 2017-04-30
MY159789A (en) 2017-01-31
RU2011128538A (ru) 2013-01-20

Similar Documents

Publication Publication Date Title
AR074603A1 (es) Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
UY28438A1 (es) Composicion de un antagonista de vegf y de un agente antiproliferativo
NZ581589A (en) Solubilized sterile injectable formulation of docetaxel without Tween 80
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
ES2527544T1 (es) Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
CO6361942A2 (es) Terapia de combinacion con epoxicetonas peptidicas
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
AR051968A1 (es) Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
CO6260019A2 (es) Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento
AR081439A1 (es) Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata
CO5590913A2 (es) Terapia de combinacion antivirica
AR068820A1 (es) Composicion farmaceutica que comprende la combinacion de diversos agentes venotonicos y vasoprotectores para el tratamiento de la insuficiencia venosa cronica y uso
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
CU20090007A6 (es) Un compuesto farmacéutico y un proceso del mismo
AR066677A1 (es) Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas.
AR069767A1 (es) Tratamiento del melanoma con peptidos timosina alfa en combinacion con activador de apoptosis de choque termico entineoplastico (hsaa)
ES2563068T3 (es) Tratamiento de esclerosis múltiple (MS) con Campath-1H
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis

Legal Events

Date Code Title Description
FB Suspension of granting procedure